Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Objectives: Chronic Viral Hepatitis B & C
- The Human Hepatitis Viruses
- Chronic HBV: A Global Health Problem
- Immigration & Global HBV: "An Asian Disease"
- HBV Transmission
- Markers of HBV Infection
- Natural History of HBV Infection
- Natural History of Chronic HBV (1)
- Natural History of Chronic HBV (2)
- Phases of Chronic HBV Infection
- Goals of Antiviral Treatment
- Who Should Be Treated?
- Guidelines of Chronic HBV Treatment (AASLD)
- HBV Genotype Impact on Disease Progression
- Response to Antiviral Therapy for HBV
- Initial Treatment Considerations
- PegINF vs. Nucleos(t)ide Analogs
- Virologic Response in HBeAg+ Chronic HBV
- Response to Therapy in HBeAg+ Chronic HBV
- Virologic Response in HBeAg- Chronic HBV
- Response to Therapy in HBeAg- Chronic HBV
- Antiviral Drug Resistance in HBV
- Antiviral Treatment Failure in HBV
- Strategies to Limit Resistance
- Monitor Response to HBV Therapy
- Screen for HBsAg
- HBV Vaccination
- Chronic Hepatitis C: A Global Health Problem
- At Risk for HCV
- Global Risk from Nosocomial HCV
- Hepatitis C - Natural History
- Progression of Fibrosis in HCV Infection
- Markers of HCV Infection
- Goals of HCV Therapy
- Interferons
- Ribavirins
- SVR by HCV Genotype in Naive Patients
- Factors Predicting a Sustained Viral Response
- Antiviral Therapy of HCV- Special Populations
- Complications in Combination Therapy for HCV
- HCV RNA: Sites for Drug Inhibition
- Chronic HCV Therapy Strategy
- HCV Protease Inhibition NS3-4A Complex
- Telaprevir + PegIFN-2a and RBV
- HCV Therapy Near New Horizons
- Summary: Chronic Hepatitis B & C
Topics Covered
- Diagnosis, Natural History and Therapy of Hepatitis B
- Diagnosis, Natural History and Therapy of Hepatitis C
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Mailliard, M. (2011, January 5). Chronic viral hepatitis B and C [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 15, 2024, from https://doi.org/10.69645/VPBA9075.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Mark Mailliard, Grant/Research Support (Principal Investigator): Gilead Sciences